ClinicalTrials.gg
CompletedNCT00349583Updated Jun 1, 2007

Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation

A Phase 4 interventional study of Topical Cyclosporine, Tears in Cataract and Dry Eye, sponsored by Innovative Medical. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2007-06-01.

Sponsored by Innovative Medical · Phase 4 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies in Cataract by Innovative Medical — none open to participants now, none under way, none of them phase 3. Cataract · Innovative Medical.

Phase 4
13 of 13
none open now
Registered
4th of 13
by date

Among the 13 studies in Cataract by Innovative Medical, this one is one of 13 in phase 4, and was the 4th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

None of the 13 studies in Cataract by Innovative Medical is open now. The open studies under Cataract, anywhere →

Where they have run

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 50 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Cataract by Innovative Medical as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy on quality of vision and dry eye signs and symptoms in patients undergoing cataract surgery using the ReZoom® multifocal IOL.

03

Conditions studied

  • Cataract
  • Dry Eye
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Males or females > 50 years old

      • Scheduled to undergo bilateral phacoemulsification with implantation of a multifocal IOL.
      • Likely to complete all study visits and able to provide
      • Visual potential of 20/25 or better

Exclusion criteria

Exclusion Criteria:

    • Prior use of topical cyclosporine

      • Known to any study medication or ingredients
      • Active ocular diseases or uncontrolled systemic disease
      • Active ocular allergies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

06

Study locations

1 site
  • Ophthalmic Consultants of Long Island
    Rockville Centre, New York 11570, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00349583
Lead sponsor
Innovative Medical
First posted
Jul 7, 2006
Last update
Jun 1, 2007

Study contacts

Eric Donnenfeld, MD
principal investigator · Ophthalmic Consultants of Long Island
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion